[Other] 10.1007/s10803-024-06436-w |
|
This post will be closed automatically in 2026-08-14 17:08
Reward10points
|
10
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
45
Why Patients Ask the Chatbot First
150
Spectral Graph Theory
50
[Full book]Initial Professional Development for Civil Engineers
20
Driving factors of digital transformation for manufacturing enterprises: a multi-case study from China
